In an analysis of 40 patients with FLT3-mutated AML treatment with gilteritinib on the ADMIRAL trial, six patients had new FLT3 mutations at time of relapse, five of which were in gatekeeper F691L and two at the NC site JM E598D (62). The gene discussed is FLT3; the disease is acute myeloid leukemia.